Anetumab ravtansine
Based on 1 Customer Validation
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models.
For research use only. We do not sell to patients.
- Purity: 98.52%
- CAS No.: 1375258-01-7
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Anetumab ravtansine (0.01-300 nM; 4 or 24 h) demonstrates potent and selective cytotoxicity of mesothelin-expressing cells with an IC50 of 0.72 nM, without affecting mesothelin-negative or nonproliferating cells[1].
Anetumab ravtansine induces a bystander effect on neighboring mesothelin-negative tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MIA PaCa-2 and HT-29; OVCAR-3; and NCI-H226
-
Concentration:0.01 nM-300 nM
-
Incubation Time:24 hours
-
Result:Inhibited cell viability with IC50s of 1.59 nM (MIA PaCa-2), 0.715 nM (HT-29), 1.59 nM (OVCAR-3), and 5.72 nM (NCI-H226), respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Subcutaneous and orthotopic xenograft models: MIA PaCa, HT29, OVCAR-3, NCI-H226 and so on (NMRI nu/nu mice: 18-25 g, 7-10 weeks old)[1]
-
Dosage:2.7 mg/kg (0.05 mg/kg DM4), 10.6 mg/kg (0.2 mg/kg DM4)
-
Administration:MF-T, or S-methyl-DM4 on days 5, 8, and 12 (mice implanted with MIA PaCa or HT29 meso cells); on days 33, 36, and 40 (OVCAR-3); on days 78, 81, 84, 127, 130, and 133 (NCI-H226); on days 15, 18, and 22 (OVCAR-3- s-05 orthotopic); on days 7, 10, and 13 (HT29 titration); Q3Dx3 starting on day 0 (PAXF736); Q3Dx3 starting on day 29 (OVCAR6719); or Q4Dx3 starting on day 34 (Meso7212) after tumor cell inoculation.
-
Result:Resulted in complete tumor eradication at 10.6 mg/kg (0.2 mg/kg DM4), lasting for at least 17 weeks following the final treatment.
Eradicated tumors in 5 out of 6 animals in the MIA PaCa-2/meso model rather than in HT-29/ meso model at 2.7 mg/kg (0.05 mg/kg DM4).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1375258-01-7
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Anetumab ravtansine]
-
Synonyms
BAY 94-9343
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anetumab ravtansine Related Classifications
HY-141606 Related Classifications
Powered by Bioz